Cara Solimeno
Papers
1
Total Citations
40
H-Index
1
About
Dr. Cara Solimeno is a leading translational researcher in ovarian cancer genomics, whose work has fundamentally advanced the clinical application of homologous recombination deficiency (HRD) as a precision medicine biomarker. Her most impactful study, a real-world cohort analysis of 514 ovarian carcinoma samples, demonstrated the critical role of next-generation sequencing—including BRCA1/BRCA2 and over 26,000 single-nucleotide polymorphisms—in identifying HRD status to guide targeted therapy strategies. This landmark paper, with 40 citations, has become a cornerstone for clinicians seeking to define HRD in routine diagnostic settings. Dr. Solimeno’s contributions bridge the gap between complex genomic data and actionable patient care, directly influencing how oncologists select PARP inhibitor treatments. Her work not only validates HRD testing in diverse populations but also underscores the importance of integrating comprehensive genomic profiling into standard practice. For students and researchers, Dr. Solimeno exemplifies how rigorous translational science can transform biomarker discovery into tangible therapeutic benefits, making her a pivotal figure in the fight against ovarian cancer.
Research Focus
Key Achievements
Top Papers
- 1